Literature DB >> 24354566

Physical and mental quality of life in adult patients with haemophilia in Belgium: the impact of financial issues.

A M Carvalhosa1, S Henrard, C Lambert, C Hermans.   

Abstract

In Belgium, where haemophilia affects approximately 1:7000 people (2011), data on patients' quality of life (QoL) is scarce. This project aims to assess physical and mental QoL (P-QoL and M-QoL) simultaneously, and to analyse the influence of different variables on these two aspects of QoL. After Ethics Committee approval, we contacted 84 adult haemophilia A (HA) and haemophilia B (HB) patients, without current inhibitors, on replacement therapy (on-demand or secondary prophylaxis), regularly followed up at our comprehensive treatment centre. Seventy-one (n = 59 HA, n = 12 HB) replied to our questionnaire, which included the SF36v2 QoL assessment forms. We analysed two groups of variables: one including variables previously associated with decreased QoL, and another including variables with unclear impact on QoL (e.g., patients' understanding of haemophilia-related issues, economical concerns). In our population (mean ± SD age: 45.2 ± 14.7 years old), P-QoL appeared more reduced than M-QoL. P-QoL was strongly influenced by the number of arthropathies while M-QoL was primarily affected by patients' concern of personal costs due to haemophilia. Among this latter group, having knowledge of insurance coverage had a positive impact on M-QoL. Scores did not depend on haemophilia type. QoL was impaired in our haemophilia patients. A simultaneous assessment of P-QoL and M-QoL confirmed the benefit of primary prophylaxis in P-QoL, while originally pointing out the major burden of patients' concerns and poor understanding of haemophilia-related economical issues on their M-QoL. This might become a particularly challenging issue in times of financial crisis.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  Belgium; Short-Form 36 Questionnaire; financial issues; haemophilia; health-related quality of life; insurance

Mesh:

Year:  2013        PMID: 24354566     DOI: 10.1111/hae.12341

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  9 in total

Review 1.  Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxis.

Authors:  Scott D Grosse; Shraddha S Chaugule; Joel W Hay
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2015-01-14       Impact factor: 2.217

2.  Social/economic costs and quality of life in patients with haemophilia in Europe.

Authors:  Marianna Cavazza; Yllka Kodra; Patrizio Armeni; Marta De Santis; Julio López-Bastida; Renata Linertová; Juan Oliva-Moreno; Pedro Serrano-Aguilar; Manuel Posada-de-la-Paz; Domenica Taruscio; Arrigo Schieppati; Georgi Iskrov; László Gulácsi; Johann Matthias Graf von der Schulenburg; Panos Kanavos; Karine Chevreul; Ulf Persson; Giovanni Fattore
Journal:  Eur J Health Econ       Date:  2016-04-05

3.  Persons with Haemophilia in Sweden- Experiences and Strategies in Everyday Life. A Single Centre Study.

Authors:  Elisabeth Brodin; Katharina S Sunnerhagen; Fariba Baghaei; Marie Törnbom
Journal:  PLoS One       Date:  2015-10-02       Impact factor: 3.240

4.  The health and economic burden of haemophilia in Belgium: a rare, expensive and challenging disease.

Authors:  Séverine Henrard; Brecht Devleesschauwer; Philippe Beutels; Michael Callens; Frank De Smet; Cedric Hermans; Niko Speybroeck
Journal:  Orphanet J Rare Dis       Date:  2014-03-21       Impact factor: 4.123

5.  Haemophilia A: health and economic burden of a rare disease in Portugal.

Authors:  Andreia Café; Manuela Carvalho; Miguel Crato; Miguel Faria; Paula Kjollerstrom; Cristina Oliveira; Patrícia R Pinto; Ramón Salvado; Alexandra Aires Dos Santos; Catarina Silva
Journal:  Orphanet J Rare Dis       Date:  2019-09-04       Impact factor: 4.123

Review 6.  International consensus recommendations on the management of people with haemophilia B.

Authors:  Daniel P Hart; Davide Matino; Jan Astermark; Gerard Dolan; Roseline d'Oiron; Cédric Hermans; Victor Jiménez-Yuste; Adriana Linares; Tadashi Matsushita; Simon McRae; Margareth C Ozelo; Sean Platton; Darrel Stafford; Robert F Sidonio; Andreas Tiede
Journal:  Ther Adv Hematol       Date:  2022-04-02

7.  The impact of extended half-life versus conventional factor product on hemophilia caregiver burden.

Authors:  Carolyn E Schwartz; Victoria E Powell; Jun Su; Jie Zhang; Adi Eldar-Lissai
Journal:  Qual Life Res       Date:  2018-02-01       Impact factor: 4.147

8.  Effectiveness of hypnosis for pain management and promotion of health-related quality-of-life among people with haemophilia: a randomised controlled pilot trial.

Authors:  Ana Cristina Paredes; Patrício Costa; Susana Fernandes; Manuela Lopes; Manuela Carvalho; Armando Almeida; Patrícia Ribeiro Pinto
Journal:  Sci Rep       Date:  2019-09-16       Impact factor: 4.379

9.  Health-related quality of life of patients with haemophilia: a cross-sectional survey in the Northeast of China.

Authors:  Jinyu Niu; Liangwen Ning; Qiao Zhang; Ze Liu; Yi Ma; Xiaoxue Xu; Qunhong Wu; Yanhua Hao; Yu Cui; Chaojie Liu
Journal:  BMJ Open       Date:  2022-02-01       Impact factor: 2.692

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.